MX355742B - Análogos deuterados del ácido 4-hidroxibutírico. - Google Patents

Análogos deuterados del ácido 4-hidroxibutírico.

Info

Publication number
MX355742B
MX355742B MX2013009368A MX2013009368A MX355742B MX 355742 B MX355742 B MX 355742B MX 2013009368 A MX2013009368 A MX 2013009368A MX 2013009368 A MX2013009368 A MX 2013009368A MX 355742 B MX355742 B MX 355742B
Authority
MX
Mexico
Prior art keywords
hydroxybutyric acid
deuterated analogs
acid deuterated
compositions
fibromyalgia
Prior art date
Application number
MX2013009368A
Other languages
English (en)
Other versions
MX2013009368A (es
Inventor
I Robert Silverman
Roger D Tung
Adam Morgan
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of MX2013009368A publication Critical patent/MX2013009368A/es
Publication of MX355742B publication Critical patent/MX355742B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/115—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se relaciona a derivados novedosos del ácido 4-hidroxibutírico y profármacos del mismo, y a sales farmacéuticamente aceptables del anterior; esta invención también proporciona composiciones farmacéuticas que comprenden un compuesto de esta invención y el uso de tales composiciones en métodos para tratar narcolepsia, fibromialgia, otros trastornos o condiciones que son tratados beneficiosamente mejorando el sueño nocturno o administrando oxibato de sodio.
MX2013009368A 2011-02-14 2012-02-14 Análogos deuterados del ácido 4-hidroxibutírico. MX355742B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161442451P 2011-02-14 2011-02-14
US201161484296P 2011-05-10 2011-05-10
PCT/US2012/024974 WO2012112492A1 (en) 2011-02-14 2012-02-14 4-hydroxybutyric acid deuterated analogs

Publications (2)

Publication Number Publication Date
MX2013009368A MX2013009368A (es) 2013-09-26
MX355742B true MX355742B (es) 2018-04-26

Family

ID=46672903

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009368A MX355742B (es) 2011-02-14 2012-02-14 Análogos deuterados del ácido 4-hidroxibutírico.

Country Status (10)

Country Link
US (5) US8759394B2 (es)
EP (1) EP2675771B1 (es)
JP (2) JP2014513046A (es)
KR (1) KR101976218B1 (es)
CN (1) CN103370289B (es)
BR (1) BR112013020620A2 (es)
ES (1) ES2804540T3 (es)
IL (1) IL227754B (es)
MX (1) MX355742B (es)
WO (1) WO2012112492A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2421808B1 (en) 2009-04-23 2013-07-31 Concert Pharmaceuticals Inc. 4-hydroxybutyric acid analogs
MX2020011961A (es) 2010-03-24 2022-04-19 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
BR112013020620A2 (pt) * 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CA2999367C (en) * 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
US10647653B2 (en) 2015-11-19 2020-05-12 Kyowa Hakko Bio Co., Ltd. Crystal of monovalent cation salt of 3-hydroxyisovaleric acid and process for producing the crystal
EP3476825A4 (en) 2016-06-24 2020-02-26 Kyowa Hakko Bio Co., Ltd. BETA-HYDROXY BETA-METHYLBUTYRIC ACID AMINO ACID SALT CRYSTAL AND METHOD FOR PRODUCING THE SAME
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
KR102510784B1 (ko) 2017-03-30 2023-03-15 엑스더블유파마 리미티드 이환형 헤테로아릴 유도체 및 이의 제조 및 용도
EP3768253A4 (en) * 2018-03-23 2021-12-29 Concert Pharmaceuticals Inc. Deuterated analogs of d-& x3b2;-hydroxybutyric acid and uses thereof
WO2020062251A1 (en) 2018-09-30 2020-04-02 Xw Laboratories, Inc. Compounds as neuronal histamine receptor-3 antagonists and uses thereof
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
KR20220133189A (ko) 2019-12-20 2022-10-04 엑스더블유파마 리미티드 4-발레릴옥시부티르산의 합성 방법
TW202139986A (zh) * 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
WO2021257886A1 (en) 2020-06-18 2021-12-23 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2021257832A1 (en) 2020-06-18 2021-12-23 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705A1 (en) 2020-10-05 2023-05-18 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學
CN113200853A (zh) * 2021-05-19 2021-08-03 宁波窦氏化学科技有限公司 一种制备丁二酸二醇酯的工艺方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA814854B (en) * 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
US4548716A (en) * 1984-07-25 1985-10-22 Lucas Boeve Method of producing ultrapure, pyrogen-free water
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
JP2727008B2 (ja) * 1989-02-01 1998-03-11 日本酸素株式会社 静菌化水の製造方法
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1248588B (it) * 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
AU749638B2 (en) * 1997-03-17 2002-06-27 Btg International Limited Therapeutic compositions
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
JP4723143B2 (ja) * 1999-09-14 2011-07-13 テファ， インコーポレイテッド γ−ヒドロキシブチレートを含むポリマーおよびオリゴマーの治療的用途
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
WO2002024715A2 (en) 2000-09-22 2002-03-28 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
WO2004006957A1 (en) 2002-07-15 2004-01-22 Alcon, Inc. Pharmaceutical compositions for otic use
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010502702A (ja) 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
US20090082380A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched rosuvastatin
AU2009302241B2 (en) * 2008-10-08 2015-10-29 Xgene Pharmaceutical Inc. GABA conjugates and methods of use thereof
EP2421808B1 (en) * 2009-04-23 2013-07-31 Concert Pharmaceuticals Inc. 4-hydroxybutyric acid analogs
BR112013020620A2 (pt) 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico

Also Published As

Publication number Publication date
IL227754A0 (en) 2013-09-30
US20130012565A1 (en) 2013-01-10
EP2675771A1 (en) 2013-12-25
IL227754B (en) 2018-01-31
CN103370289B (zh) 2015-09-09
BR112013020620A2 (pt) 2016-10-04
JP6692319B2 (ja) 2020-05-13
US20160326086A1 (en) 2016-11-10
KR101976218B1 (ko) 2019-05-07
JP2017165747A (ja) 2017-09-21
US20140343119A1 (en) 2014-11-20
MX2013009368A (es) 2013-09-26
KR20140008391A (ko) 2014-01-21
CN103370289A (zh) 2013-10-23
US10040748B2 (en) 2018-08-07
US20190100484A1 (en) 2019-04-04
US8759394B2 (en) 2014-06-24
WO2012112492A1 (en) 2012-08-23
US9309182B2 (en) 2016-04-12
ES2804540T3 (es) 2021-02-08
EP2675771B1 (en) 2020-04-08
US20210403407A1 (en) 2021-12-30
JP2014513046A (ja) 2014-05-29

Similar Documents

Publication Publication Date Title
MX355742B (es) Análogos deuterados del ácido 4-hidroxibutírico.
HK1167641A1 (en) 4-hydroxybutyric acid analogs 4-
MX349159B (es) Derivados deuterados de ivacaftor.
MY178621A (en) Deuterated cftr potentiators
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
PH12015501108B1 (en) Treatment of pulmonary disease
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
IN2014DN09434A (es)
NZ726366A (en) Syk inhibitors
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
BR112015022197A2 (pt) tratamento de cataplexia
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
EP2418945A4 (en) Mineral salt-sulfuric acid compositions and methods for their use
WO2012094598A3 (en) Pharmaceutical compositions of iron for oral administration
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
MX2015008187A (es) Inhibidores de alk deuterados.
MX2014003803A (es) Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
IN2013DN02555A (es)
AR092104A1 (es) LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)
IN2014KN01113A (es)

Legal Events

Date Code Title Description
FG Grant or registration